Recombinant Human DR3/TNFRSF25 Fc Chimera Protein, CF Summary
(Gln25-Phe201) & (Arg29-Phe201)
Accession # Q93038.2
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS and EDTA.|
|Reconstitution||Reconstitute at 100 μg/mL in sterile PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Death receptor 3 (DR3), also known as lymphocyte-associated receptor of death (LARD), WSL-1, APO3, TRAMP and TR3, is a glycoprotein belonging to the TNF receptor superfamily (TNFRSF) (1 - 5). DR3 was formerly designated TNFRSF12 when it was thought to be a receptor for TWEAK/TNFSF12 (6). However, work disavowed the DR3:TWEAK interaction and DR3 is now designated TNFRSF 25 (7). By alternative splicing, at least 11 distinct human DR3 transcripts encoding secreted or type I membrane proteins exist (7). The human DR3 isoform 1 cDNA encodes a 417 amino acid residue (aa) transmembrane precursor with a 24 aa signal peptide, a 175 aa extracellular domain containing four cysteine-rich repeats and two potential N-glycosylation sites, a 21 aa transmembrane region and a 195 aa cytoplasmic region with one death domain. DR3 is one of six within the TNF R superfamily that contains a death domain in its cytooplasmic region. It is most closely related to TNF R1 and FAS/CD95, sharing 29% and 23% aa sequence identity, respectively. DR3 is expressed primarily in tissues enriched in lymphocytes. Whereas naïve B and T cells express multiple truncated DR3 isoforms but not the transmembrane isoform 1, upon T cell activation, expression of the transmembrane DR3 isoform 1 predominates. TL1A/VEGI, a TNF superfamily ligand, has been shown to bind and activate DR3 (8). Depending on the cell context, ligation of DR3 by TL1A can trigger one of two signaling pathways. On primary T cells, TL1A induces NF-kappa-B activation and a costimulatory signal to increase IL-2 responsiveness and the secretion of proinflammatory cytokines. However, in a tumor cell line, TF-1, TL1A has been shown to induce caspase activity and apoptosis. In DR3-null mice, an impairment of negative selection and anti-CD3-mediated thymocyte apoptosis is observed.
- Chinnaiyan, A.M., et al. (1996) Science 274:990.
- Kitson, J., et al. (1996) Nature 384:372.
- Bodmer, J-L., et al. (1997) Immunity 6:79.
- Screaton, G.R. et al. (1997) Proc. Nat. Acad. Sci. USA 94:4615.
- Marsters, S.A. et al. (1996) Curr. Biol. 6:1669.
- Marsters, S.A. et al. (1998) Curr. Biol. 8:525.
- Kaptein, A. et al. (2000) FEBS Lett. 485:135.
- Migone, T-S. et al. (2002) Immunity 16:479.
Citations for Recombinant Human DR3/TNFRSF25 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 7
Filter your results:
A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3
Authors: A Zwolak, SR Chan, P Harvilla, S Mahady, AA Armstrong, L Luistro, N Tamot, D Yamada, M Derebe, S Pomerantz, M Chiu, R Ganesan, P Chowdhury
Scientific Reports, 2022-11-29;12(1):20538.
Applications: ELISA Development
TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses
Authors: B Oriol-Tord, A Olvera, C Duran-Cast, A Llano, B Mothe, M Massanella, J Dalmau, C Ganoza, J Sanchez, ML Calle, B Clotet, J Martinez-P, E Negredo, J Blanco, D Hartigan-O, C Brander, M Ruiz-Riol
J Immunol, 2020-11-11;0(0):.
Sample Types: Whole Cells
An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease
Authors: AW Clarke, L Poulton, D Shim, D Mabon, D Butt, M Pollard, V Pande, J Husten, J Lyons, C Tian, AG Doyle
Sample Types: Recombinant Protein
Applications: ELISA Capture
Directed evolution of a soluble human DR3 receptor for the inhibition of TL1A induced cytokine secretion
Authors: I Levin, M Zaretsky, A Aharoni
PLoS ONE, 2017-03-09;12(3):e0173460.
Sample Types: N/A
Applications: ELISA Developmet
A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1.
Authors: Hedl M, Abraham C
Proc Natl Acad Sci U S A, 2014-09-02;111(37):13451-6.
Sample Types: Whole Cells
Progranulin-derived Atsttrin directly binds to TNFRSF25 (DR3) and inhibits TNF-like ligand 1A (TL1A) activity.
Authors: Liu, Cui, Li, Xing-Xia, Gao, Wei, Liu, Wen, Liu, De-Shan
PLoS ONE, 2014-03-20;9(3):e92743.
Sample Types: Protein
Applications: Binding Assay
Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells.
Authors: Krysov SV, Krysov</LastName><ForeNam SV</Initia, Rowley TF, Al-Shamkhani A
Mol. Cancer Ther., 2007-02-01;6(2):703-11.
Sample Types: Whole Cells
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human DR3/TNFRSF25 Fc Chimera Protein, CF
Average Rating: 4.5 (Based on 2 Reviews)
Have you used Recombinant Human DR3/TNFRSF25 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image